跳至主要内容
临床试验/NCT00349440
NCT00349440已完成4 期

Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy

Innovative Medical1 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
93
试验地点
1
主要终点
Dry Eye Symptoms

研究概览

简要总结

The purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic solution 0.05% (Restasis, Allergan) on the signs and symptoms of dry eye in patients undergoing LASIK or photorefractive keratectomy (PRK).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males or females > 18 years old
  • Mild-moderate symptoms of dry eye prior to surgery
  • Scheduled to undergo bilateral LASIK or PRK
  • Likely to complete all study visits and able to provide informed consent

排除标准

  • Prior use of topical cyclosporine within the last 1 year
  • Known contraindications to any study medication or ingredients
  • Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females.
  • Ocular disorders
  • Active ocular diseases or uncontrolled systemic disease
  • Active ocular allergies

研究组 & 干预措施

1

Active Comparator

干预措施: Cyclosporine, Refresh Plus (Drug)

2

Placebo Comparator

干预措施: Cyclosporine, Refresh Plus (Drug)

结局指标

主要结局

Dry Eye Symptoms

时间窗: 1.5 years

次要结局

  • Dry eye signs(1.5 yrs)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验